TY - JOUR
T1 - Successful thrombolysis in postoperative patients with acute massive pulmonary embolism
AU - Zhang, Kedong
AU - Zeng, Xiansheng
AU - Zhu, Caixia
AU - Xu, Lei
AU - Fu, Xin
AU - Jiang, Hua
AU - Wang, Jian
AU - Lu, Wenju
N1 - Funding Information:
This work was supported by Changjiang Scholars and Innovative Research Team in University grant (IRT0961), Guangdong Natural Science Foundation team grant (1035101200300000), and Guangzhou Department of Education Yangcheng Scholarship (10A058S).
PY - 2013/2
Y1 - 2013/2
N2 - Purpose: The standard medical management for patients with acute massive pulmonary embolism (MPE) is systemic thrombolysis. However, it is generally thought that recent surgeries are a contraindication to thrombolytic therapy. In this study, we evaluated the efficacy and safety of systemic thrombolysis for postoperative patients with acute MPE and assessed the risk of bleeding. Methods: A retrospective review was performed on 21 postoperative patients with MPE in a timeframe of five years (from 2005 to 2010). The criteria for study inclusion were postoperative patients who received systemic thrombolysis for confirmed acute MPE within three weeks after surgery. Results: Seventeen postoperative patients, including men (12) and women (five) aged 53 ± 16 (range 23-71) years, were treated with systemic thrombolysis. Significant haemodynamic improvement (shock index < 0.9) was observed in 16 of 17 cases (94%). The remaining patient (6%) died of cardiac arrest within 24. h. No major bleeding complication was observed. Sixteen patients survived and remained stable for 34 ± 16 (range 11-52) days until hospital discharge. Conclusion: Recent surgery is not an absolute contraindication to systemic thrombolysis. Further, to obtain a successful outcome, it is crucial to exclude patients who have received neurosurgical operations or those with other contraindications to thrombolytic therapy.
AB - Purpose: The standard medical management for patients with acute massive pulmonary embolism (MPE) is systemic thrombolysis. However, it is generally thought that recent surgeries are a contraindication to thrombolytic therapy. In this study, we evaluated the efficacy and safety of systemic thrombolysis for postoperative patients with acute MPE and assessed the risk of bleeding. Methods: A retrospective review was performed on 21 postoperative patients with MPE in a timeframe of five years (from 2005 to 2010). The criteria for study inclusion were postoperative patients who received systemic thrombolysis for confirmed acute MPE within three weeks after surgery. Results: Seventeen postoperative patients, including men (12) and women (five) aged 53 ± 16 (range 23-71) years, were treated with systemic thrombolysis. Significant haemodynamic improvement (shock index < 0.9) was observed in 16 of 17 cases (94%). The remaining patient (6%) died of cardiac arrest within 24. h. No major bleeding complication was observed. Sixteen patients survived and remained stable for 34 ± 16 (range 11-52) days until hospital discharge. Conclusion: Recent surgery is not an absolute contraindication to systemic thrombolysis. Further, to obtain a successful outcome, it is crucial to exclude patients who have received neurosurgical operations or those with other contraindications to thrombolytic therapy.
KW - Acute massive pulmonary embolism
KW - Postoperative thrombolysis
UR - http://www.scopus.com/inward/record.url?scp=84880041421&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84880041421&partnerID=8YFLogxK
U2 - 10.1016/j.hlc.2012.08.055
DO - 10.1016/j.hlc.2012.08.055
M3 - Article
C2 - 23068907
AN - SCOPUS:84880041421
SN - 1443-9506
VL - 22
SP - 100
EP - 103
JO - Heart Lung and Circulation
JF - Heart Lung and Circulation
IS - 2
ER -